Clinical Research Directory
Browse clinical research sites, groups, and studies.
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Summary
To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2024-02-22
Completion Date
2026-06-30
Last Updated
2025-08-06
Healthy Volunteers
No
Conditions
Interventions
Ivosidenib,Venetoclax,gilteritinib,Selinexor
if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)
Locations (1)
Blood Hospital
Tianjin, China